Latest News
BIOSECURE and Catalent deal could bag more biz for Thermo
BIOSECURE and Catalent deal could bag more biz for Thermo
Thermo Fisher Scientific highlighted the BIOSECURE Act and the pending Catalent/Novo deal as potential drivers for its CDMO business during its Q1 earnings call.
Deal-Making
Multiply Labs and Stanford Laboratory for Cell and Gene therapy Manufacturing (LCGM) have collaborated to use automation technology for manufacturing cell therapies.
The partnership between Panasonic Holdings, Shinobi Therapeutics, and Kyoto’s University Center for iPS Cell Research and Application (CiRA) aims to develop a cost-effective manufacturing platform for T-cell therapies.
Facilities & Capacity
Higher yields, improved media, and perfusion are driving network optimization at Roche and led to the recent divestment of a 330,000 L California facility to CDMO Lonza.
Merck KGaA has begun construction on an 18,000 square-meter research center at its global headquarters in Darmstadt, Germany.
Global Markets
Thermo Fisher Scientific highlighted the BIOSECURE Act and the pending Catalent/Novo deal as potential drivers for its CDMO business during its Q1 earnings call.
Sartorius has closed its first quarter positively “in line” with expectations but highlights China as a continued market weakness.
Regulations
The US FDA has approved Beqvez (fidanacogene elaparvovec), Pfizer’s adeno-associated virus (AAV) based gene therapy for the treatment of hemophilia B.
CDMO AGC Bio will supply lentiviral vectors for Orchard Therapeutics’ metachromatic leukodystrophy (MLD) gene therapy, approved in the US this week.
Therapeutic Class
The US FDA has approved Beqvez (fidanacogene elaparvovec), Pfizer’s adeno-associated virus (AAV) based gene therapy for the treatment of hemophilia B.
With a roughly flat quarter in sales revenue, J&J said it will continue to expand capacity and cites Carvykti as a key driver for growth in 2024.
Upstream & Downstream Processing
Higher yields, improved media, and perfusion are driving network optimization at Roche and led to the recent divestment of a 330,000 L California facility to CDMO Lonza.
Nigel Titchener-Hooker, professor and dean of engineering at University College London, guided delegates at BioProcess International Europe in Vienna, Austria, on a tour through drug-development history.